Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1749 • ACR Convergence 2024
Safety and Long-term Efficacy of CD19-CAR T-cell Therapy in 30 Patients with Autoimmune Disease
Melanie Hagen¹, Fabian Müller², Andreas Wirsching¹, Carlo Tur¹, Tobias Krickau³, Markus Metzler⁴, Laura Bucci¹, Christina Bergmann⁵, Janina Auth¹, Jule Taubmann⁶, Panagiotis Garantziotis⁷, Sebastian Boeltz⁸, Soraya Kharboutli⁹, Silvia Spoerl⁹, Simon Völkl¹⁰, Michael Aigner⁹, Sascha Kretschmann⁹, Ingrid Vasova⁹, Andreas MAckensen¹¹, Ricardo Grieshaber-Bouyer⁸ and Georg Schett¹², ¹Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ²Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Germany, ³Department of Pediatrics and Adolscent Medicine, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Bayern, Germany, ⁴Department of Pediatrics and Adolscent Medicine, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ⁵Department Internal Medicine III, Friedrich-Alexander-University (FAU) Erlangen-Nurnber, Frankfurt, Germany, ⁶Friedrich-Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁷Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ⁸Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ⁹Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ¹⁰Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Bayern, Germany, ¹¹Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ¹²Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: Treating autoimmune diseases like Systemic Lupus erythematosus (SLE), Idiopathic Inflammatory Myositis (IIM) or Systemic Sclerosis (SSc) is challenging and often requires life-long immunosuppressive therapy.…
Abstract Number: 1789 • ACR Convergence 2024
Multi-omic Profiling Identifies Pathogenic Pro-inflammatory Human Monocytes/Macrophages in Systemic Lupus Erythematosus
Lais Osmani¹, Min Shin², Sang Jin Lee³, Helen Cai⁴, Won Jae Seong², Hyoungsu Kim², Jongjin Yoo², Angela Mirabella², William Bracamonte², Mario Felix⁵, Jong Gyun Ahn², Hong-Jai Park², Juan Young⁶, Junghee Shin², Serhan Unlu⁷, Noelle Yoo², Edward Doherty², Jiaye Chen², Chenxi Li², Gabriela Sanchez-Zuno², Caroline Valdez⁴, Thuy Tran⁸, Mei Dong², Sang Kim², Christine Ko⁹, Sungyong You¹⁰, Jose Gomez¹¹, Richard Bucala¹² and Insoo Kang², ¹Yale, New Haven, CT, ²Yale University School of Medicine, Internal Medicine (Rheumatology, Allergy & Immunology), New Haven, CT, ³Division of Rheumatology, Kyungpook National University Hospital, Dae gu, Republic of Korea, ⁴Yale University School of Medicine, New Haven, CT, ⁵Yale, Hamden, CT, ⁶Yale University School of Medicine, Psychiatry, New Haven, CT, ⁷Cleveland Clinic, Internal Medicine, Cleveland, OH, ⁸Yale University School of Medicine, Internal Medicine (Medical Oncology), New Haven, CT, ⁹Yale University School of Medicine, Dermatology and Pathology, New Haven, CT, ¹⁰Cedars-Sinai Medical Center, Surgery and Computational Biomedicine, Los Angeles, CA, ¹¹Yale University School of Medicine, Internal Medicine (Pulmonary, Critical Care & Sleep), New Haven, CT, ¹²Yale University School of Medicine, Internal Medicine (Rheumatology, Allergy & Immunology) and Pathology, New Haven, CT
Background/Purpose: Systemic lupus erythematosus (SLE or lupus) is a clinically heterogeneous autoimmune disease, in which emerging evidence implicates the innate immune system, particularly monocytes and…
Abstract Number: 1809 • ACR Convergence 2024
Melanocytes Are Driven Toward an Antigen Presentation Phenotype Through UV-Induced Keratinocyte Crosstalk and Exposure to Type I Interferons in Patients with Cutaneous Lupus Erythematosus
Rezvan Moallemian, Lin Zhang, Mehrnaz Gharaee-Kermani, Allison Billi, Amy Hurst, Benjamin Klein and J. Michelle Kahlenberg, University of Michigan, Ann Arbor, MI
Background/Purpose: Cutaneous lupus erythematosus (CLE) encompasses various lesion morphologies, but photosensitivity and high type I interferon (IFN) responses are a unifying theme amongst all CLE…
Abstract Number: 1961 • ACR Convergence 2024
Salivary and Lacrimal Glands Ultrasonography in Systemic Lupus Erythematosus Patients
Mohammadrafi Damirchi¹, Nafiseh Abdolahi², Fatemeh Hosseini³, Mohadeseh Mohammadi³, Mina Khosravi⁴, Zahra Niakan¹ and Siavash Abbasi³, ¹Golestan Rheumatology Research Center, Golestan University of Medical Sciences, Gorgan, Iran, Gorgan, Iran, ²Golestan Rheumatology Research Center, Golestan University of Medical Sciences, Gorgan, Iran, Melbourne, Australia, ³Department of Radiology, Golestan University of Medical Sciences, Gorgan, Iran, Gorgan, Iran, ⁴Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran, Tehran, Iran
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune inflammatory condition that can manifest in various ways, such as oral and eye-related symptoms, which may overlap…
Abstract Number: 2373 • ACR Convergence 2024
The Construction and Validation of Sub-phenotype-specific Genetic Risk Scores in Systemic Lupus Erythematosus: A Novel Approach Using Large-scale Biobank Data
Sarah Reid¹, Johanna Sandling², Pascal Pucholt³, Ahmed Sayadi⁴, Martina Frodlund⁵, Karoline Lerang⁶, Andreas Jönsen⁷, Christopher Sjowall⁸, Iva Gunnarsson⁹, Ann-Christine Syvänen², Anders Bengtsson⁷, Øyvind Molberg¹⁰, Elisabet Svenungsson¹¹, Anna Rudin¹², Solbritt Rantapaa-Dahlqvist¹³, Lars Rönnblom² and Dag Leonard², ¹Uppsala University, Medical Sciences, Uppsala, Sweden, ²Uppsala University, Uppsala, Sweden, ³Rheumatology and Science for Life Laboratory, Department of Medical Sciences, Uppsala university, Uppsala, Sweden, ⁴Uppsala, Uppsala, Sweden, ⁵Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden, ⁶Oslo University Hospital, Oslo, Norway, ⁷Lund University, Lund, Sweden, ⁸Linköping University, Linköping, Sweden, ⁹Karolinska Institute, Stockholm, Sweden, ¹⁰Oslo University Hospital, Department of Rheumatology, Oslo, Nepal, ¹¹Karolinska Institutet, Stockholm, Sweden, ¹²Institute of Medicine, University of Gothenburg, Gothenburg, Sweden, ¹³Umeå University, Umeå, Sweden
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with a heterogeneous clinical picture. This study aimed to link genetic SLE predisposition with relevant clinical…
Abstract Number: 2391 • ACR Convergence 2024
Identification of Patients with ANA Negative and Double Stranded DNA Positive: What Is the Significance in Daily Rheumatology Practise
Güllü Sandal Uzun¹, Emily Apsley² and David Isenberg², ¹University College London, London, England, United Kingdom, ²University College London, London, United Kingdom
Background/Purpose: The anti-nuclear antibody (ANA test) is a sensitive screening tool used when assessing patients with possible autoimmune rheumatic diseases (ARD). Homogeneous staining positivity is…
Abstract Number: 2410 • ACR Convergence 2024
A Novel Treatment Response Measure for SLE Clinical Trials (TRM-SLE): Selection of Domains and Candidate Measures
Kathryn Connelly¹, Rachel Koelmeyer¹, Darshini Ayton¹, Lavanya Rajagopala², Ambika Wahklu², John May³, Raychel Barallon⁴, Rangi Kandane-Rathnayake⁵, Laura Eades¹, kate Gregory¹ and Eric Morand⁶, and the TRM-SLE Taskforce, ¹Monash University, Melbourne, Victoria, Australia, ²Monash Health, Melbourne, Victoria, Australia, ³Monash Medical Centre, Richmond, Victoria, Australia, ⁴Monash Health, Clayton, Victoria, Australia, ⁵Monash University, Clayton, Victoria, Australia, ⁶School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia
Background/Purpose: The success of randomised controlled trials (RCTs) in SLE has been hampered by limitations of current outcome measures, contributing to negative or discordant trial…
Abstract Number: 2426 • ACR Convergence 2024
Multi-OMICs Analysis Including Lipidomics to Correlate Baseline OMICs Profiles with Disease Activity and Response to Different Immunomodulatory Treatments in Patients with Systemic Lupus Erythematosus – An Exploratory Pilot Study Using a Multi-OMICs Approach
Michaela Koehm¹, Samuel Rischke², Robert Gurke³, Gerd Geißlinger⁴ and Frank Behrens¹, ¹University Hospital Goethe University Frankfurt and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany, ²Goethe University Frankfurt, Institute of Clinical Pharmacology, Frankfurt, Germany, ³Goethe University Frankfurt, Institute of Clinical Pharmacology and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, ⁴Goethe University Frankfurt, Institute of Clinical Pharmacology and Fraunhofer Insitute for Translational Medicine and Pharmacology ITMP, Frankfurt
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a very heterogeneous clinical presentation and severity. Despite the variety of treatment options available,…
Abstract Number: 2547 • ACR Convergence 2024
Neurophysiological Phenotypes Are Uncoupled from Toll-like Receptor-Mediated Peripheral Disease in a Mouse Model of Neuropsychiatric Symptoms of Systemic Lupus Erythematosus
Cecilia Stumpf¹, Vanessa Rodriguez¹ and Carla Cuda², ¹Northwestern University, Chicago, ²Northwestern University, Chicago, IL
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with diverse clinical presentations, including neuropsychiatric symptoms (NPSLE). Despite being a major cause of morbidity…
Abstract Number: 2622 • ACR Convergence 2024
Quality of Care for Childhood-Onset Lupus Nephritis: Suboptimal Completion of Disease Activity Monitoring
Emily Smitherman¹, Justin Leach¹, Aimee Hersh², Melissa Mannion¹, Jinoos Yazdany³ and Jeffrey Curtis⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Utah, Salt Lake City, UT, ³UCSF, San Francisco, CA, ⁴University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Poorly controlled childhood-onset lupus nephritis (cLN) can lead to end-stage kidney disease (ESKD), requiring kidney replacement therapies with substantial financial and quality of life…
Abstract Number: 0001 • ACR Convergence 2024
Type I Interferon and Anifrolumab Effects on Bone Marrow and Blood Plasma Cells in Systemic Lupus Erythematosus
Diana Alzamareh¹, Nida Pellett², Daria Krenitsky², Wesley Durrett¹, Javier Rangel-Moreno¹, Jennifer Anolik² and Jennifer Barnas¹, ¹University of Rochester, Rochester, NY, ²University of Rochester Medical Center, Rochester, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of pathogenic anti-nuclear antibodies (ANA) by plasma cells (PC). Importantly, long-lived plasma…
Abstract Number: 0095 • ACR Convergence 2024
Expansion of Brain T Cell Subsets Outside of the Choroid Plexus in Murine Models of Neuropsychiatric Manifestations of Systemic Lupus Erythematosus
Minjung Kim¹, Cecilia Stumpf², Hadijat Makinde¹, Mohammad Khan¹, Vanessa Rodriguez², Tyler Therron², Jeremy Tilstra³, Deborah Winter⁴ and Carla Cuda¹, ¹Northwestern University, Chicago, IL, ²Northwestern University, Chicago, ³University of Pittsburgh, Pittsburgh, PA, ⁴Northwestern University, Skokie, IL
Background/Purpose: Unclear mechanisms underlying diffuse NPSLE (psychosis, anxiety disorder, cognitive dysfunction) may lead to the devastating impact of this disease on patients’ health-related quality-of-life, representing…
Abstract Number: 0170 • ACR Convergence 2024
Association of General Physical Functioning, Valued Life Activity (VLA) Disability, and Use of Accommodations with Depressive Symptoms Among Individuals with Systemic Lupus Erythematosus (SLE)
Patti Katz¹, Laura Plantinga², Maria Dall'Era³, Kamil Barbour⁴, Kurt Greenlund⁴ and Jinoos Yazdany⁵, ¹UCSF, San Rafael, CA, ²University of California, San Francisco, San Francisco, CA, ³UCSF, Corte Madera, CA, ⁴CDC, Alpharetta, GA, ⁵University of California San Francisco, San Francisco, CA
Background/Purpose: Physical functioning (PF) is usually assessed generally in SLE rather than as difficulty performing specific activities, and measurements rarely incorporate accommodations (ACCs) that may…
Abstract Number: 0195 • ACR Convergence 2024
Screening for Social Determinants of Health in Patients with SLE: A Point-of-Care Feasibility Study
S. Sam Lim¹, Vijay R. Nadipelli², Michelle Bruno³, Daphne Lew⁴, Bernard Rubin⁵, Charmayne M. Dunlop-Thomas⁶, Kristi R. Mitchell³, Lydia Demetriou⁷, Jeffrey Berko³ and Alfred Kim⁸, ¹Emory University, Atlanta, GA, ²GSK, Medical Evidence Generation, Philadelphia, PA, ³Atlas Clarity, LLC, San Francisco, CA, ⁴Center for Biostatistics and Data Science, Institute for Informatics, Data Science, and Biostatistics, Washington University School of Medicine and Washington University School of Medicine, Division of Rheumatology, Department of Medicine, St Louis, MO, ⁵Progentec Diagnostics, Inc., Oklahoma City, OK, ⁶Emory University School of Medicine, Department of Medicine, Division of Rheumatology, Atlanta, GA, ⁷GSK, Global Clinical Operations, Brentford, United Kingdom, ⁸Washington University School of Medicine, Division of Rheumatology, Department of Medicine, St Louis, MO
Background/Purpose: Currently, social determinants of health (SDoH; conditions in which people live) are not routinely screened for in US outpatient rheumatology clinics.1 SLE disproportionally affects…
Abstract Number: 0368 • ACR Convergence 2024
Development and Validation of a Patient-centered Self-evaluation Questionnaire in Systemic Lupus Erythematosus: LUPIN®
Marc Scherlinger¹, Jean-Francois Kleinmann¹, Antonin Folliasson², Marianne Riviere³, Raphaelle Rybak⁴, Sabine Malivoir⁵, Jean-François Viallard⁶, Estibaliz Lazaro⁷, Christophe Richez⁸, Irene Machelart⁹, Nadine Magy-Bertrand¹⁰, Audrey Gorse¹¹, Gilles Blaison¹², Julien Campagne¹³, Benjamin Dervieux¹⁴, Thomas Moulinet¹⁵, Roland Jaussaud¹⁶, Pascal Roblot¹⁷, Mathieu Puyade¹⁷, Amélie Servettaz¹⁸, Pauline Orquevaux¹⁸, Julie le Scanff¹⁹, DANIEL WENDLING²⁰, Marc Andre²¹, Ludovic Trefond²¹, Perrine SMETS²², Nicolas Baillet²³, Christophe Deligny²⁴, Xavier Mariette²⁵, ARNAUD HOT²⁶, Emmanuelle David²⁷, Laurent Perard²⁸, Estelle Jean²⁹, Sarah Permal³⁰, Denis WAHL³¹, Christian Agard³², François Chasset³³, Baptiste Hervier³⁴, Pasquer Ronan², Mickael Martin¹⁷, Ludivine Lebourg³⁵, Frederic Renou³⁶, Loic Raffray³⁶, Elisabeth Diot³⁷, Cecile Fermont³⁸, Thierry Martin³⁹, Anne-Sophie Korganow³⁹, Jacques-Eric Gottenberg⁴⁰, Jean Sibilia⁴¹ and Zahir Amoura⁴², ¹Strasbourg University Hospital - National reference center for autoimmune disease, Rheumatology, Strasbourg, France, ²Hometrix Health, Paris, France, ³Association Francaise du Lupus et autres maladies autoimmunes (AFL+), Metz, France, ⁴Association Francaise du Lupus et autres maladies autoimmunes (AFL+), Paris, France, ⁵APHP Pitié Salpêtrière - National reference center for autoimmune disease, Internal Medicine, Paris, France, ⁶CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac, FR, Bordeaux, France, ⁷Bordeaux University Hospital, Pessac, France, ⁸Université de Bordeaux, Bordeaux, France, ⁹CH de Bayonne - Competence center for autoimmune diseases, Internal Medicine, Bayonne, France, ¹⁰CHU de Besancon - Competence center for autoimmune diseases, Internal Medicine, Besançon, France, ¹¹CH de Chambery - Competence center for autoimmune diseases, Internal Medicine, Chambery, France, ¹²CH de Colmar - Competence center for autoimmune diseases, Internal Medicine, Colmar, France, ¹³Hôpital Robert Schuman - Competence center for autoimmune diseases, Internal Medicine, Metz, France, ¹⁴CH de Mulhouse - Competence center for autoimmune diseases, Internal Medicine, Mulhouse, France, ¹⁵CHRU de Nancy, Vandœuvre-lès-Nancy, France, ¹⁶CHU de Nancy - Competence center for autoimmune diseases, Internal Medicine, Nancy, France, ¹⁷CHU de Poitiers - Competence center for autoimmune diseases, Internal Medicine, Poitiers, France, ¹⁸CHU de Reims - Competence center for autoimmune diseases, Internal Medicine, Reims, France, ¹⁹CH - Competence center for autoimmune diseases, Internal Medicine, Villefranche-sur-Saone, France, ²⁰University Hospital, Besançon, France, ²¹CHU de Clermont-Ferrand - National reference center for autoimmune disease, Internal Medicine, Clermont-Ferrand, France, ²²Clermont Ferrand University Hospital - National reference center for autoimmune disease, Internal Medicine, Clermont-Ferrand, France, ²³CH de Basse-Terre - Competence center for autoimmune diseases, Internal Medicine, Basse-Terre, France, ²⁴University Hospital of Martinique - National reference center for autoimmune disease, Internal Medicine, Fort-de-France, Martinique, ²⁵Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France, ²⁶Service de Médecine interne, Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France, ²⁷HCL - Croix Rousse, Internal Medicine, Lyon, France, ²⁸Hopital Saint-Joseph, Internal Medicine, Lyon, France, ²⁹APHM - La Timone, Internal Medicine, Marseille, France, ³⁰CH Mayotte - CH Wallis-et-Futuna, Internal Medicine, Mamoudzou, Mayotte, ³¹Lorraine University, Nancy, France, ³²CHU de Nantes - National reference center for autoimmune disease, Internal Medicine, Nantes, France, ³³Dermatology, Hôpital Tenon, Paris, France, ³⁴APHP Saint-Louis - National reference center for autoimmune disease, Internal Medicine, Paris, France, ³⁵CHU de Rouen, Internal Medicine, Rouen, France, ³⁶CHU La Réunion - Competence center for autoimmune diseases, Internal Medicine, Saint-Denis, Reunion, ³⁷CHU de Tours - Competence center for autoimmune diseases, Internal Medicine, Tours, France, ³⁸CH de Valence - Competence center for autoimmune diseases, Internal Medicine, Valence, France, ³⁹Strasbourg University Hospital, National reference center for autoimmune disease, Clinical Immunology, Strasbourg, France, ⁴⁰Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, ⁴¹Strasbourg University Hospital, National reference center for autoimmune disease, Rheumatology, Strasbourg, France, ⁴²French National Reference Centre for Systemic Lupus Erythematosus, Pitié-Salpêtrière Hospital, Paris, France
Background/Purpose: Systemic Lupus Erythematosus (SLE) features unpredictable disease activity fluctuations, making flare hard to detect and significantly impairing quality of life. This highlights the need…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].